Kinase signaling pathways as potential targets in the treatment of Parkinson’s disease

References

• Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann. NY Acad. Sci.991, 1–14 (2003).
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science276(5321), 2045–2047 (1997).
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM et al. Alpha-synuclein in Lewy bodies. Nature388(6645), 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature392(6676), 605–608 (1998).
   PubMed Web of Science ®Google Scholar
• Bonifati V, Rizzu P, van Baren MJ et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science299(5604), 256–259 (2003).
   PubMed Web of Science ®Google Scholar
• Canet-Aviles RM, Wilson MA, Miller DW et al. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA101(24), 9103–9108 (2004).
   PubMed Web of Science ®Google Scholar
• Hod Y, Pentyala SN, Whyard TC, El–Maghrabi MR. Identification and characterization of a novel protein that regulates RNA–protein interaction. J. Cell. Biochem.72(3), 435–444 (1999).
   PubMed Web of Science ®Google Scholar
• Valente EM, Salvi S, Ialongo T et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol.56(3), 336–341 (2004).
   PubMed Web of Science ®Google Scholar
• Paisan-Ruiz C, Jain S, Evans EW et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron44(4), 595–600 (2004).
   PubMed Web of Science ®Google Scholar
• Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron44(4), 601–607 (2004).
   PubMed Web of Science ®Google Scholar
• Funayama M, Hasegawa K, Ohta E et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol.57(6), 918–921 (2005).
   PubMed Web of Science ®Google Scholar
• Funayama M, Hasegawa K, Kowa H et al. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol.51(3), 296–301 (2002).
   PubMed Web of Science ®Google Scholar
• Bonifati V. Parkinson’s disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson’s disease genetics. Eur. J. Hum. Genet.14(10), 1061–1062 (2006).
   Google Scholar
• Bras JM, Guerreiro RJ, Ribeiro MH et al. G2019S dardarin substitution is a common cause of Parkinson’s disease in a Portuguese cohort. Mov. Disord.20(12), 1653–1655 (2005).
   PubMed Web of Science ®Google Scholar
• Ozelius LJ, Senthil G, Saunders-Pullman R et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N. Engl. J. Med.354(4), 424–425 (2006).
   PubMed Web of Science ®Google Scholar
• Lesage S, Durr A, Tazir M et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N. Engl. J. Med.354(4), 422–423 (2006).
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science298(5600), 1912–1934 (2002).
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci.30(3), 151–159 (2005).
   PubMed Web of Science ®Google Scholar
• West AB, Moore DJ, Biskup S et al. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA102(46), 16842–16847 (2005).
   PubMed Web of Science ®Google Scholar
• Greggio E, Jain S, Kingsbury A et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis.23(2), 329–341 (2006).
   PubMed Web of Science ®Google Scholar
• Smith WW, Pei Z, Jiang H et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci.9(10), 1231–1233 (2006).
   PubMed Web of Science ®Google Scholar
• MacLeod D, Dowman J, Hammond R et al. The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron52(4), 587–593 (2006).
   PubMed Web of Science ®Google Scholar
• Gloeckner CJ, Kinkl N, Schumacher A et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Gen.15(2), 223–232 (2006).
   PubMed Web of Science ®Google Scholar
• West AB, Moore DJ, Choi C et al. Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Gen.16(2), 223–232 (2007).
   PubMed Web of Science ®Google Scholar
• Jaleel M, Nichols RJ, Deak M et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochem. J.405(2), 307–317 (2007).
   PubMedGoogle Scholar
• Guo L, Gandhi PN, Wang W et al. The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell. Res.313(16), 3658–3670 (2007).
   PubMed Web of Science ®Google Scholar
• Smith WW, Pei Z, Jiang H et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA102(51), 18676–18681 (2005).
   PubMed Web of Science ®Google Scholar
• Greggio E, Lewis PA, van der Brug MP et al. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem.102(1), 93–102 (2007).
   PubMed Web of Science ®Google Scholar
• Korr D, Toschi L, Donner P et al. LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal.18(6), 910–920 (2006).
   PubMed Web of Science ®Google Scholar
• Ito G, Okai T, Fujino G et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson’s disease. Biochemistry46(5), 1380–1388 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis PA, Greggio E, Beilina A et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Comm.357(3), 668–671 (2007).
   PubMed Web of Science ®Google Scholar
• Li X, Tan YC, Poulose S et al. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants. J. Neurochem.103(1), 238–247 (2007).
   PubMed Web of Science ®Google Scholar
• Miklossy J, Qing H, Guo JP et al. Lrrk2 and chronic inflammation are linked to pallido–ponto–nigral degeneration caused by the N279K tau mutation. Acta Neuropathol.114(3), 243–254 (2007).
   Google Scholar
• Giasson BI, Covy JP, Bonini NM et al. Biochemical and pathological characterization of Lrrk2. Ann. Neurol.59(2), 315–322 (2006).
   PubMedGoogle Scholar
• Zhu X, Siedlak SL, Smith MA, Perry G, Chen SG. LRRK2 protein is a component of Lewy bodies. Ann. Neurol.60(5), 617–618; author reply 618–619 (2006).
   Google Scholar
• Higashi S, Biskup S, West AB et al. Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain. Brain Res.1155, 208–219 (2007).
   PubMed Web of Science ®Google Scholar
• Melrose HL, Kent CB, Taylor JP et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience147(4), 1047–1058 (2007).
   Google Scholar
• Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol.17(7), 592–598 (2007).
   Google Scholar
• Paglini G, Kunda P, Quiroga S, Kosik K, Caceres A. Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. J. Cell Biol.143(2), 443–455 (1998).
   PubMed Web of Science ®Google Scholar
• White LR, Toft M, Kvam SN, Farrer MJ, Aasly JO. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson’s disease. J. Neurosci. Res.85(6), 1288–1294 (2007).
   PubMed Web of Science ®Google Scholar
• Rouse J, Cohen P, Trigon S et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell78(6), 1027–1037 (1994).
   PubMed Web of Science ®Google Scholar
• Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene15(18), 2169–2177 (1997).
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Hasegawa M, Dohmae N et al. alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol.4(2), 160–164 (2002).
   PubMed Web of Science ®Google Scholar
• Frasier M, Walzer M, McCarthy L et al. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp. Neurol.192(2), 274–287 (2005).
   PubMedGoogle Scholar
• Ahn NG, Resing KA. Cell biology. Lessons in rational drug design for protein kinases. Science308(5726), 1266–1267 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science308(5726), 1318–1321 (2005).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev.6(7), 541–555 (2007).
   Google Scholar
• Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev.15(1), 62–68 (2005).
   PubMed Web of Science ®Google Scholar
• Biskup S, Moore DJ, Celsi F et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol.60(5), 557–569 (2006).
   PubMed Web of Science ®Google Scholar
• Hatano T, Kubo S, Imai S et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Gen.16(6), 678–690 (2007).
   PubMed Web of Science ®Google Scholar
• Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol. Ther.114(3), 261–277 (2007).
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron39(6), 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• Lotharius J, O’Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem.275(49), 38581–38588 (2000).
   PubMed Web of Science ®Google Scholar
• Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science294(5545), 1346–1349 (2001).
   PubMed Web of Science ®Google Scholar
• Karunakaran S, Diwakar L, Saeed U et al. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson’s disease: protection by α-lipoic acid. FASEB J.21(9), 2226–2236 (2007).
   PubMed Web of Science ®Google Scholar
• Hunot S, Vila M, Teismann P et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson’s disease. Proc. Natl Acad. Sci. USA101(2), 665–670 (2004).
   PubMed Web of Science ®Google Scholar
• Lotharius J, Falsig J, van Beek J et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci.25(27), 6329–6342 (2005).
   PubMed Web of Science ®Google Scholar
• Maroney AC, Finn JP, Connors TJ et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem.276(27), 25302–25308 (2001).
   PubMed Web of Science ®Google Scholar
• Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther.288(2), 421–427 (1999).
   PubMed Web of Science ®Google Scholar
• Bennett BL, Sasaki DT, Murray BW et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA98(24), 13681–13686 (2001).
   PubMed Web of Science ®Google Scholar
• Wang W, Shi L, Xie Y et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease. Neurosci. Res.48(2), 195–202 (2004).
   PubMed Web of Science ®Google Scholar
• Klein C, Grunewald A, Hedrich K. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology66(7), 1129–1130; author reply 1129–1130 (2006).
   Web of Science ®Google Scholar
• Zadikoff C, Rogaeva E, Djarmati A et al. Homozygous and heterozygous PINK1 mutations: considerations for diagnosis and care of Parkinson’s disease patients. Mov. Disord.21(6), 875–879 (2006).
   Google Scholar
• Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol.6(7), 652–662 (2007).
   PubMed Web of Science ®Google Scholar
• Beilina A, Van Der Brug M, Ahmad R et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl Acad. Sci. USA102(16), 5703–5708 (2005).
   PubMed Web of Science ®Google Scholar
• Silvestri L, Caputo V, Bellacchio E et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Gen.14(22), 3477–3492 (2005).
   PubMed Web of Science ®Google Scholar
• Sim CH, Lio DS, Mok SS et al. C-terminal truncation and Parkinson’s disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum. Mol. Gen.15(21), 3251–3262 (2006).
   PubMed Web of Science ®Google Scholar
• Taymans JM, Van den Haute C, Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem.98(3), 951–961 (2006).
   PubMed Web of Science ®Google Scholar
• Hoepken HH, Gispert S, Morales B et al. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis.25(2), 401–411 (2007).
   Google Scholar
• Petit A, Kawarai T, Paitel E et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem.280(40), 34025–34032 (2005).
   PubMed Web of Science ®Google Scholar
• Wang D, Qian L, Xiong H et al. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl Acad. Sci. USA103(36), 13520–13525 (2006).
   PubMed Web of Science ®Google Scholar
• Clark IE, Dodson MW, Jiang C et al.Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature441(7097), 1162–1166 (2006).
   PubMed Web of Science ®Google Scholar
• Park J, Lee SB, Lee S et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature441(7097), 1157–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Yang Y, Gehrke S, Imai Y et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl Acad. Sci. USA103(28), 10793–10798 (2006).
   PubMed Web of Science ®Google Scholar
• Greene JC, Whitworth AJ, Kuo I et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA100(7), 4078–4083 (2003).
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Friedlein A, Imai Y et al. Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J. Biol. Chem.280(5), 3390–3399 (2005).
   PubMedGoogle Scholar
• Kitada T, Pisani A, Porter DR et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl Acad. Sci. USA104(27), 11441–11446 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Fleming SM, Palacino JJ et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem.278(44), 43628–43635 (2003).
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Pisani A, Haburcak M et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron45(4), 489–496 (2005).
   PubMed Web of Science ®Google Scholar
• Pridgeon JW, Olzmann JA, Chin LS, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol.5(7), e172 (2007).
   PubMed Web of Science ®Google Scholar
• Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol.11(3), 297–305 (2001).
   PubMed Web of Science ®Google Scholar
• Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene20(33), 4457–4465 (2001).
   PubMed Web of Science ®Google Scholar
• Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol.21(3), 893–901 (2001).
   PubMed Web of Science ®Google Scholar
• Kim AH, Yano H, Cho H et al. Akt1 regulates a JNK scaffold during excitotoxic apoptosis. Neuron35(4), 697–709 (2002).
   PubMedGoogle Scholar
• Fallon L, Belanger CM, Corera AT et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol.8(8), 834–842 (2006).
   PubMed Web of Science ®Google Scholar
• Kim RH, Peters M, Jang Y et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer cell7(3), 263–273 (2005).
   PubMed Web of Science ®Google Scholar
• Yang Y, Gehrke S, Haque ME et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl Acad. Sci. USA102(38), 13670–13675 (2005).
   PubMed Web of Science ®Google Scholar